Needham and now Barclays are bullish on CF franchise
Vertex Pharm stays ahead of the CF game - Barclays
Barclays says following the VRTX analyst event at NACFC, they remain bullish
on the CF franchise. Lack of dose response can be attributed to therapeutic
window of CF drugs. Although investors have questioned the apparent lack of
dose response among the three tested doses of VX-809, they believe this can be
attributed to drug-drug interaction between Kalydeco and VX-809. Of note, this
is why a higher Kalydeco dose was used in the trial vs. the currently FDA
approved dose. VRTX has in-house PK/PD data that suggests the appropriate
therapeutic window for VX-809 is around the 600 mg once daily dose. Firm says
they understand the concerns around dose response, they believe the 600 mg
dose is the minimally effective dose that will be taken forward in the clinic.
What's ahead for the CF program? VRTX confirmed it has an end of Phase II
meeting scheduled with the FDA in 4Q12, after which the company plans to
initiate Phase III.